SAB Biotherapeutics, Inc. (SABS) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SABS Revenue Growth
Revenue Breakdown (FY 2022)
SABS's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
SABS Revenue Analysis (2019–2025)
As of May 8, 2026, SAB Biotherapeutics, Inc. (SABS) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, SABS's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $60.9 million in 2021.
Revenue diversification analysis shows SABS's business is primarily driven by Grant (100%). With over half of revenue concentrated in Grant, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ARGX (+241.6% YoY), HALO (+37.6% YoY), and ADMA (+11.0% YoY), SABS has underperformed the peer group in terms of revenue growth. Compare SABS vs ARGX →
SABS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SABSCurrent | $0 | -100.0% | - | - | |
 ARGX | $4.2B | +241.6% | +151.7% | 23.4% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 ADMA | $510M | +11.0% | +64.6% | 37.5% |
SABS Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $0 | - | $-48,953,363 | - |
| 2024 | $1.3M | -40.9% | $-3,470,185 | -262.4% | $-42,910,520 | -3244.9% |
| 2023 | $2.2M | -90.6% | $-1,506,000 | -67.3% | $-38,075,000 | -1700.5% |
| 2022 | $23.9M | -60.7% | $20.6M | 86.2% | $-28,918,000 | -121.0% |
| 2021 | $60.9M | +10.2% | $59.2M | 97.3% | $-13,393,000 | -22.0% |
| 2020 | $55.2M | +1504.8% | $55.2M | 100.0% | $20.6M | 37.2% |
| 2019 | $3.4M | - | $3.4M | 100.0% | $-8,674,000 | -252.0% |
See SABS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SABS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SABS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSABS — Frequently Asked Questions
Quick answers to the most common questions about buying SABS stock.
Is SABS's revenue growth accelerating or slowing?
SABS revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is SABS's long-term revenue growth rate?
SAB Biotherapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is SABS's revenue distributed by segment?
SABS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.